Research Article - (2021) Volume 7, Issue 1
1Department of Chemistry, Faculty of Arts and Sciences, Gaziantep University, Turkey
2Department of Medical Biochemistry, School of Medicine, SANKO University, Turkey
3Department of Molecular Medicine, Graduate Institute of Education, SANKO University, Turkey
4Department of Bioinformatics and Computational Biology, Gaziantep University, Turkey
5Department of Medical Biology, School of Medicine, SANKO University, Turkey
6Department of Biological and Biomedical Sciences, Graduate Education Institute, SANKO University, Turkey
7Department of Marine Technologies, Iskenderun Technical University, Turkey
8Tashkent Vocational High School, Selçuk University, Turkey
9Institute of Materials Science, Christian-Albrechts-University, Germany
10Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan
11Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Turkey
Received Date: October 17, 2020; Accepted Date: January 23, 2021; Published Date: January 30, 2021
Citation: Al-Khafaji K, Saygili EI, Taskin-Tok T, Cetin Z, Sayın S, et al. (2021) Investigation of Promising Antiviral Candidate Molecules based on Algal Phlorotannin for the Prevention of COVID-19 Pandemic by in silico Studies. Biochem Mol Biol Vol.7 No.1:3.
Background: Coronavirus disease 19 (COVID-19) is a highly contagious and pathogenic viral infection. Research has been stepped up due to the lack of vaccine for this viral infection and no effective treatment against this new virus. In order to control the spread, the effectiveness of algal phlorotannin-derived natural molecules on COVID-19, which are easy to obtain, maintainable and have antiviral efficacy by focusing on the Spike (S) protein of the virus, was investigated by in silico methods.
Materials and methods: In this study, molecular docking was performed to highlight the emerging role of the top three molecules amongst the selected 11 compounds against SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2.
Results and Discussion: An in silico model of algal molecules interactivity on SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2 receptor was observed. Results suggested that based on in silico model, out of algal phlorotannin ligands, only a diecol showed good binding affinity toward SARS CoV-2-RBD/ACE2 interface, compared as remdesivir, chloroquine and hydroxychloroquine sulfate. Moreover within these potential molecules based phlorofucofuroeckol B can also be protector for only TMPRSS2.
Conclusion: In future, these results may be aid to direction of the design and development of potent drugs for COVID-19 treatment based on the severity of infection.
ADMET; COVID-19; Spike (S) Protein; Algal phlorotannin; Molecular docking
Coronaviruses are enveloped RNA viruses that cause enteric, respiratory and central nervous system diseases in various animals and humans [1]. Coronavirus surface protein spikes (S) mediate entry into target cells by binding to a cellular receptor and then fusing the viral envelope with a host cell membrane [2]. SARS-CoV Spike protein (SARS-S) uses Angiotensin Converting Enzyme 2 (ACE2) as the host cell entry receptor [3,4]. Cleavage of the S protein by host cell proteases is essential for viral infectivity and responsible enzymes are potential targets for intervention [2]. The SARS-S enters angiotensin converting enzyme 2 (ACE2) as the input receptor [3] and uses cellular Transmembrane Serine Protease 2 (TMPRSS2) for S protein preparation [5]. The SARS-S/ACE2 interface has been identified at the atomic level and the effectiveness of ACE2 use has been found to be the main determinant of SARS-CoV contamination [6].
Outbreaks from viral infectious diseases that have led to mass deaths throughout history show how they can threaten public health on a global scale. The current situation clearly shows that antiviral treatments that are effective against various virus strains should be developed immediately in the prevention and treatment of viruses. In the development of antiviral drug agent, molecules containing innovative functional groups are of great importance in the structure and effectiveness of drugs. The targeted properties of functional groups or systems and their effect on drug composition are very important [7]. At this point, the use of in silico methods has an important place in the development of antiviral drug agents’ researches. In predicting the interactions of bioactive molecules and biological life systems with each other, the use of in silico methods saves considerable time, labor and cost.
In recent years, one of the alternative and sustainable ways of developing effective treatments against the related virus is the identification of potent agents. In this study, algae; it is a rich source of effective molecules such as phlorotannins, polysaccharides, pigments, glycolipids, catechin, terpenoids, polyhydroxyburates. Algae with their rich functional contents; It has an important potential with its biological activities such as anticancer, antimicrobial, anti-inflammatory and antiviral [8]. Phlorotannin is a class of polyphenol compounds produced by brown seaweed as secondary metabolites and biosynthesized through the acetate malonate pathway [9,10]. These compounds have attracted considerable research interest for their broad health benefits and potential uses in a range of therapeutics [11,12]. It has demonstrated that phlorotannins can have anti-diabetic, anti-cancer, anti-oxidation, antibacterial, radio protective and anti-HIV properties [13,14].
Based on this information, using in silico approaches within the scope of the study, the inhibitory effect of 11 compounds (Phloroglucinol, Eckol, Fucodiphloroechol-G, Phlorofucofuroeckol A, 7-Phloroeckol, Dieckol, 6,6'-Bieckol, Diphloroethohydroxycarmalol, 8,8'-Bieckol, Phlorofucofuroeckol B, Catechin) on the mechanism of action of SARS-CoV-2 was investigated. The potent molecules activity has been investigated and evaluated against the ACE2 and TMPRSS2 proteins to which SARS-CoV-2 binds.
Ligand-protein docking
The data set was composed of 11 compounds (Table 1) which were obtained from literature [15-22]. These natural compounds produce from algal organisms that shown antiviral activity were also remarked in introduction part of the study. Nowadays, remdesivir is the most hopeful SARS-CoV-2 drug, although Food and Drug Administration (FDA) has also confirmed the utilization of chloroquine and hydroxychloroquine for emergency coronavirus treatment [23]. The following process, Discovery Studio (DS) 2019 (BIOVIA, 2016) was applied to arrange and to exert the docking calculations and also to define docking interactions of the selected compounds- SARS CoV-2-RBD/ACE2 and the selected compounds- SARS CoV-2-Spike/TMPRSS2 complexes. The crystal structures of target models, SARS CoV-2-RBD/ACE2 (PDB: 2AJF) was retrieved from protein data bank [24,25] and SARS CoV-2- Spike/TMPRSS2 was occurred based on Meng et al. study [26] by using Homology modelling for docking processes. The ligands, the selected eleven compounds were sketched and optimized in gas phase using the CHARMm force field [27] to prepare an ensemble of docking study with no atomic clashes in their geometries.
Name | Herbal name | Chemical Structure, SMILES | Molecular Formula |
---|---|---|---|
1 | Phloroglucinol | Oc1cc(O)cc(O)c1 | C6 H6 O3 |
2 | Eckol | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4cc(O)cc(O)c4Oc23)c1 | C18 H12 O9 |
3 | Fucodiphloroechol – G | Oc1cc(O)c(Oc2cc(O)cc(O)c2Oc3cc(O)cc(O)c3c4c(O)cc(O)cc4O)c(O)c1 | C24 H18 O12 |
4 | Phlorofucofuroeckol A | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4c(Oc23)c(O)cc5oc6c(Oc7cc(O)cc(O)c7)c(O)cc(O)c6c45)c1 | C30 H18 O14 |
5 | 7-Phloroeckol | Oc1cc(O)c(Oc2cc(O)c3Oc4c(Oc5cc(O)cc(O)c5)c(O)cc(O)c4Oc3c2)c(O)c1 | C24 H16 O12 |
6 | Dieckol | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4cc(Oc5c(O)cc(Oc6c(O)cc(O)c7Oc8cc(O)cc(O)c8Oc67)cc5O)cc(O)c4Oc23)c1 | C36 H22 O18 |
7 | 6,6-Bieckol | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4c(Oc23)c(O)cc(O)c4c5c(O)cc(O)c6Oc7c(Oc8cc(O)cc(O)c8)c(O)cc(O)c7Oc56)c1 | C36 H22 O18 |
8 | Diphloroethohydroxycarmalol | Oc1cc(O)c(Oc2cc3Oc4c(O)c(Oc5cc(O)cc(O)c5)c(O)c(O)c4Oc3c(O)c2O)c(O)c1 | C24 H16 O14 |
9 | 8,8-Bieckol | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4cc(O)c(c(O)c4Oc23)c5c(O)cc6Oc7c(O)cc(O)c(Oc8cc(O)cc(O)c8)c7Oc6c5O)c1 | C36 H22 O18 |
10 | Phlorofucofuroeckol B | Oc1cc(O)cc(Oc2c(O)cc(O)c3Oc4cc5oc6c(Oc7cc(O)cc(O)c7)c(O)cc(O)c6c5c(O)c4Oc23)c1 | C30 H18 O14 |
11 | Catechin | O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c3ccc(O)c(O)c3 | C15 H14 O6 |
*Remdesivir | Remdesivir | CCC(CC)COC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4 | C27 H35 N6 O8 P |
*Chloroquine | Chloroquine | CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 | C18 H26 Cl N3 |
*Hydroxychloroquine sulfate | Hydroxychloroquine sulfate | CCN(CCO)CCC[C@H](C)Nc1ccnc2cc(Cl)ccc12 | C18 H28 Cl N3 O5 S |
Table 1: Chemical structures of 11 compounds produce from algal organisms.
In addition, their conformational analyses were investigated by using DS 2019. On the other hand, both virus models were prepared using DS tools and minimized until the root mean square deviation (RMSD) reaches the lower value of 0.05 kcal/mol Å2. The binding site tool in DS software and the related literatures information were used to detect binding site of the SARS CoV-2- RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2 against the selected eleven natural structures.
Molecular docking is one of the most common procedures for generating ligand pose inside the pocket and determining the key residues which interact with ligand. Therefore, docking studies were executed using the docking software AutodockFR (ADFR) software [28] with the AutoGridFr (AGFR version 1.0) [29,30] which is responsible for building configuration file which contains the data for running controlled flexible docking by detecting the residues of the complex’s binding site. This enables ligands reaches buried grooves after running docking calculations by running of ADFR with presumptive parameters for all complexes [31]. The docking results for each complex was ranked according to the binding energy, root mean square deviation (RMSD) and interaction types.
In silico ADMET prediction
As known that the effectiveness and safety of a potential drug agent depends essentially on the biotransformations that occur in the organism. Therefore, drug-likeness properties including Lipinski [32] and Veber [33] tests for the selected compounds and remdesivir, chloroquine and hydroxychloroquine sulfate are effective drugs against SARS CoV-2 as positive controls were used and filtered by using DS 2019 [34]. In the following step, ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction was applied for the same compounds with help of ADMET subprotocol of Discovery Studio 2019 software using the prediction model by Egan et al. [35,36]. Water solubility (log S), CaCO2 cell permeability for the prediction of oral drug absorption, Human ether-a-go-go related gene (hERG) inhibition and toxicity descriptors (AMES toxicity, Hepatotoxicity and Skin sensitization) were calculated. In summary, it was applied to allow a deeper insight into applicability of the selected compounds to be safe for potential drug development against SARS-CoV- 2.
Molecular docking study
For effective docking process, a potential drug agent should fit the active site of an individual target. That means nonbonding interactions including hydrogen bond, electrostatic and hydrophobic have a tremendous impact on docking results. The binding energies of the molecules shape complementarity are also an indispensable condition. The key is to define the correct binding mode with most stable interactions. Binding energy values of the selected ligands represent their affinity to form durable interactions inside the pockets of both targets. A low binding energy value signifies a strong binding and vice versa [37]. Based on these information, out of 11 ligands, only a 33% showed good binding affinity toward SARS CoV-2-RBD/ACE2 interface, compared as remdesivir, chloroquine and hydroxychloroquine sulfate. However, this ratio raised to 42% when 11 ligands docked to SARS CoV-2-Spike/TMPRSS2 interface as presented in the Table 2. What is intriguing about the data in this table is that both of Dieckol (6) and Phlorofucofuroeckol B (10) are ranked of top three against both targets. We attended to explore the top three compounds and their interactions with each of the selected complex. The top one is Dieckol (6) when it binds to SARS CoV-2- RBD/ACE2. The interactions of Dieckol (6) with the lowest binding affinity (-7.406 kcal/mol) as displayed in Table 3 which forms five hydrogen bonds with Gly354, Ala386 of ACE2 and six hydrogen bonds with Lys390, Gln396, Tyr491, Asp393 residues of SARS CoV- 2-RBD protein. Besides hydrogen bond, there are five electrostatic interactions with Lys390, Asp392 and Asp393 of ACE2 and eight hydrophobic interactions with four residues of ACE2 protein (Phe356, Met383, Ala386 and Ala387) and also two residues of SARS-CoV-2-RBD protein (Tyr440 and Val404) (Figure 1). While Dieckol comes in second rank of binding affinity (-9.039 kcal/mol) to bind with SARS CoV-2-Spike/TMPRSS2. Where it formed three hydrogen bonds and five hydrophobic interactions as shown in Figure 2, where Dieckol (6) interacted in the interface of SARS CoV-2-Spike/TMPRSS2, through forming two hydrogen bonds with both Phe194 and Pro288 and five vander Waal interactions with Pro288, Phe357 and Pro354 of TMPRSS2 protein. Besides, it forms one hydrogen bond through Asp820 of SARS CoV-2- Spike. Another significant finding is related to 8,8-Bieckol (9) which ranked second when it bound to SARS CoV-2-RBD/ACE2 complex with the binding affinity of – 7.253 kcal/mol. First, 8,8-Bieckol (9) interacted with SARS CoV-2-RBD/ACE2 interface through two conventional hydrogen bonds all of them with ACE2 protein residues (Arg393) and two carbon-hydrogen bonds with Thr324 and Gly354 as presented in Figure 1. Furthermore, the residues (Ala386 and Ala387) of ACE2 form three hydrophobic interactions with 8,8-Bieckol (9). Despite these interactions, SARS CoV-2-RBD interacted with 8,8-Bieckol (9) through nine hydrogen bonds (Arg395, Gly490, Asp392, Gly391 and Gly490) and three electrostatic interactions through Arg395 and Asp392 of SARS CoV-2-RBD, and also one hydrophobic interaction with Ile489 residue in the related protein, (Figure 1).
Name | Donor HB | Accpt HB | logS | Caco-2 | loghERG | AMES toxicity | Hepatotoxicity | Skin sensitization |
---|---|---|---|---|---|---|---|---|
Range | 2/20 | 2/20 | -6.5/0.5 | <25 poor, >500 great | <-5 | True: Toxic/False: Non-Toxic | ||
1 | 3 | 2 | -0.384 | 269.113 | -3.257 | Non-Mutagen | False | Strong |
2 | 6 | 6 | -2.619 | 17.844 | -5.201 | Non-Mutagen | False | Strong |
3 | 10 | 9 | -2.883 | 0.919 | -6.411 | Non-Mutagen | False | Strong |
4 | 9 | 9 | -4.279 | 1.791 | -6.85 | Mutagen | False | None |
5 | 8 | 8 | -3.484 | 2.728 | -6.292 | Non-Mutagen | False | Strong |
6 | 11 | 12 | -5.313 | 0.162 | -7.929 | Non-Mutagen | False | Strong |
7 | 12 | 12 | -3.89 | 0.344 | -6.761 | Non-Mutagen | False | Strong |
8 | 10 | 10 | -3.265 | 0.327 | -6.506 | Non-Mutagen | False | Strong |
9 | 12 | 12 | -3.993 | 0.219 | -6.805 | Non-Mutagen | False | Strong |
10 | 9 | 9 | -4.325 | 1.539 | -6.913 | Mutagen | False | None |
11 | 5 | 5 | -2.591 | 57.005 | -4.784 | Non-Mutagen | False | Strong |
*Remdesivir | 5 | 17 | -5.107 | 33.727 | -6.788 | Non-Mutagen | True | None |
*Chloroquine | 2 | 6 | -3.198 | 438.709 | -5.941 | Mutagen | True | None |
*Hydroxychloroquine | 1 | 4 | -3.82 | 1403.192 | -5.766 | Mutagen | True | None |
Table 2: ADMET analysis of 11 compounds and positive controls* (Remdesivir, chloroquine and hydroxychloroquine sulfate) for SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2).
Turning now to another promising compound that is 6,6-Bieckol (7) which has lowest binding score (-9.177 kcal//mol), with four hydrogen bonds with when it binds to SARS CoV-2-Spike/ TMPRSS2. Where it forms four hydrogen bonds with SARS CoV- 2 Spike protein residues (Thr827, Val826 and Asn824) and four hydrophobic interactions with TMPRSS2 residues (Pro288, Phe194 and Pro354) as shown in Figure 2. On the other hand, phlorofucofuroeckol B (10) ranked as third when it screened against SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2 of binding affinity (-6.939 and -8.515 kcal/mol), respectively. This compound interacted three hydrogen bonds with the residues of SARS CoV-2-RBD (Lys390, Gln396 and Tyr491) and five electrostatic interactions with Lys390 and Asp393 residues and also three hydrophobic interactions with Tyr440, Tyr491 and Val404 of SARS CoV-2-RBD. In addition, it interacted through forming one hydrogen bond (Glu37) and three hydrophobic interactions with ACE2 protein residues (Ala386), Figure 1. The compound, phlorofucofuroeckol B (10) has a good ability to establish four conventional hydrogen bonds with TMPRSS2 residues (Phe357, Thr287, Glu289, Cys241) and one carbon-hydrogen bonds with TMPRSS2 residues (Pro288) as shown in Figure 2. Also, it interacted through forming two electrostatic interactions with Arg240 of TMPRSS2 and five hydrophobic interactions with TMPRSS2 residues (Phe357, Ala243, Pro288, Pro354 and Ala243). This indicative interaction tells us that phlorofucofuroeckol B (10) prefers to bind with TMPRSS2 protein.
Besides these docking calculations, the same docking processes were also applied by using three potent drugs against SARS CoV- 2 as three positive controls: remdesivir, is noted for its capacity to reduce the viral load in the lung tissue of mice infected with the MERS-CoV virus, improving lung function and damage to lung tissue [38] and, chloroquine and hydroxychloroquine sulfate are further used anti-malarial drugs recommended by the FDA against SARS CoV-2 [23]. (Figure 3 and Table 4). Compared with control compounds and also with the orientation and conformation of the studied top three compounds at the SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2 pockets allow more potent binding (Table 3) and efficient interactions (Figure 1 and Figure 2). In summary, it was revealed that dieckol (6) and phlorofucofuroeckol B (10) prefer to bind with ACE2 and TMPRSS2 receptors more than SARS CoV-2 Spike and SARS CoV- 2-RBD proteins. So that the compound (dieckol) can be protector for the cell receptors (ACE2 and TMPRSS2). Phlorofucofuroeckol B can also be protector for only TMPRSS2.
Compound Name | SARS CoV-2-RBD/ACE2 | SARS CoV-2-Spike/TMPRSS2 | ||
---|---|---|---|---|
Binding energy (kcal/mol) | RMSD (Å) | Binding energy (kcal/mol) | RMSD (Å) | |
1 | -4.272 | 0.859 | -4.952 | 0.474 |
2 | -5.412 | 1.223 | -7.257 | 1.173 |
3 | -6.039 | 2.041 | -7.325 | 3.791 |
4 | -6.672 | 2.302 | -7.942 | 2.125 |
5 | -6.229 | 1.290 | -8.283 | 1.512 |
6 | -7.406 | 2.021 | -9.039 | 3.679 |
7 | -6.651 | 1.516 | -9.177 | 1.058 |
8 | -6.188 | 3.532 | -8.313 | 3.601 |
9 | -7.253 | 2.786 | -8.285 | 2.260 |
10 | -6.939 | 1.955 | -8.515 | 1.801 |
11 | -5.196 | 1.291 | -6.240 | 1.619 |
*Remdesivir | -6.537 | 3.562 | -8.011 | 2.269 |
*Chloroquine | -5.234 | 2.310 | -5.738 | 1.429 |
*Hydroxychloroquine sulfate | -5.185 | 1.873 | -5.920 | 2.235 |
Table 3: Docking Results of 11 compounds toward SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2 complex.
SARS CoV-2-RBD/ACE2 | |||||
---|---|---|---|---|---|
Interactions-Remdesivir | Distance Å | Bonding | Bonding Types | Target | Ligand |
A: GLN325: HN - Remdesivir: N30 | 2.7938 | Hydrogen Bond | Conventional Hydrogen Bond | A: GLN325: HN | Remdesivir: N30 |
E: GLY490: HN - Remdesivir: N26 | 2.4758 | Hydrogen Bond | Conventional Hydrogen Bond | E: GLY490: HN | Remdesivir: N26 |
Remdesivir: H47 - A: MET383: O | 2.9175 | Hydrogen Bond | Conventional Hydrogen Bond | A: MET383: O | Remdesivir: H47 |
A: GLY354: HA1 - Remdesivir: N26 | 2.5265 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLY354: HA1 | Remdesivir: N26 |
E: GLY488: HA1 - Remdesivir: N26 | 2.6010 | Hydrogen Bond | Carbon Hydrogen Bond | E: GLY488: HA1 | Remdesivir: N26 |
E: GLY490: HA1 - Remdesivir: N26 | 3.0246 | Hydrogen Bond | Carbon Hydrogen Bond | E: GLY490: HA1 | Remdesivir: N26 |
E: ILE489: HN - Remdesivir | 3.0680 | Hydrogen Bond | Pi-Donor Hydrogen Bond | E: ILE489: HN | Remdesivir |
Remdesivir - A: PRO321 | 4.2456 | Hydrophobic | Pi-Alkyl | A: PRO321 | Remdesivir |
Remdesivir - A: ALA384 | 4.7492 | Hydrophobic | Pi-Alkyl | A: ALA384 | Remdesivir |
Remdesivir - E: ILE489 | 4.7178 | Hydrophobic | Pi-Alkyl | E: ILE489 | Remdesivir |
Interactions-Chloroquine | Distance Å | Bonding | Bonding Types | Target | Ligand |
Chloroquine: H40 - A: ALA386: O | 2.8499 | Hydrogen Bond | Carbon Hydrogen Bond | A: ALA386: O | Chloroquine: H40 |
Chloroquine: H42 - A: GLU37: OE1 | 2.8475 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLU37: OE1 | Chloroquine: H42 |
Chloroquine-A: PHE356 | 5.7629 | Hydrophobic | Pi-Pi T-shaped | A: PHE356 | Chloroquine |
Chloroquine- A: PHE356 | 5.1758 | Hydrophobic | Pi-Pi T-shaped | A: PHE356 | Chloroquine |
Chloroquine: CL20 - A: PRO321 | 4.0220 | Hydrophobic | Alkyl | A: PRO321 | Chloroquine: CL20 |
Chloroquine: CL20 - A: MET383 | 3.5397 | Hydrophobic | Alkyl | A: MET383 | Chloroquine: CL20 |
Chloroquine - A: MET383 | 4.7875 | Hydrophobic | Pi-Alkyl | A: MET383 | Chloroquine |
Interactions-Hydroxychloroquine sulfate | Distance Å | Bonding | Bonding Types | Target | Ligand |
Hydroxychloroquine sulfate: H27 - E: TYR491: OH | 3.0534 | Hydrogen Bond | Carbon Hydrogen Bond | E: TYR491: OH | Hydroxychloroquine sulfate: H27 |
Hydroxychloroquine sulfate: H43 - A: MET383: O | 2.6589 | Hydrogen Bond | Carbon Hydrogen Bond | A: MET383: O | Hydroxychloroquine sulfate: H43 |
Hydroxychloroquine sulfate - A: PHE356 | 5.1956 | Hydrophobic | Pi-Pi T-shaped | A: PHE356 | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: MET383 | 4.9256 | Hydrophobic | Pi-Alkyl | A: MET383 | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: ALA386 | 5.4130 | Hydrophobic | Pi-Alkyl | A: ALA386 | Hydroxychloroquine sulfate |
Interactions-Dieckol | Distance Å | Bonding | Bonding Types | Target | Ligand |
E: LYS390: HZ2 - Dieckol: O45 | 2.4977 | Hydrogen Bond | Conventional Hydrogen Bond | E: LYS390: HZ2 | Dieckol: O45 |
E: LYS390: HZ3 - Dieckol: O45 | 2.9174 | Hydrogen Bond | Conventional Hydrogen Bond | E: LYS390: HZ3 | Dieckol: O45 |
Dieckol: H59 - A: GLY354: O | 2.9561 | Hydrogen Bond | Conventional Hydrogen Bond | A: GLY354: O | Dieckol: H59 |
Dieckol: H64 - A: ALA386: O | 2.8949 | Hydrogen Bond | Conventional Hydrogen Bond | A: ALA386: O | Dieckol: H64 |
Dieckol: H70 - E: GLN396: OE1 | 2.8332 | Hydrogen Bond | Conventional Hydrogen Bond | E: GLN396: OE1 | Dieckol: H70 |
Dieckol: H71 - E: TYR491: OH | 1.9152 | Hydrogen Bond | Conventional Hydrogen Bond | E: TYR491: OH | Dieckol: H71 |
Dieckol: H75 - E: ASP393: OD2 | 2.7816 | Hydrogen Bond | Conventional Hydrogen Bond | E: ASP393: OD2 | Dieckol: H75 |
A: GLY354: HA1 - Dieckol: O16 | 2.5775 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLY354: HA1 | Dieckol: O16 |
A: GLY354: HA1 - Dieckol: O19 | 2.9464 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLY354: HA1 | Dieckol: O19 |
A: GLY354: HA2 - Dieckol: O19 | 3.0035 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLY354: HA2 | Dieckol: O19 |
E: LYS390: HZ3 - Dieckol | 2.3468 | Hydrogen Bond;Electrostatic | Pi-Cation;Pi-Donor Hydrogen Bond | E: LYS390: HZ3 | Dieckol |
E: ASP392: OD1 - Dieckol | 4.4474 | Electrostatic | Pi-Anion | E: ASP392: OD1 | Dieckol |
E: ASP392: OD2 - Dieckol | 3.3188 | Electrostatic | Pi-Anion | E: ASP392: OD2 | Dieckol |
E: ASP393: OD1 - Dieckol | 4.5729 | Electrostatic | Pi-Anion | E: ASP393: OD1 | Dieckol |
E: ASP393: OD1 - Dieckol | 3.9606 | Electrostatic | Pi-Anion | E: ASP393: OD1 | Dieckol |
E: TYR440 - Dieckol | 5.2778 | Hydrophobic | Pi-Pi Stacked | E: TYR440 | Dieckol |
A: PHE356 - Dieckol | 5.8437 | Hydrophobic | Pi-Pi T-shaped | A: PHE356 | Dieckol |
A: PHE356 - Dieckol | 5.2454 | Hydrophobic | Pi-Pi T-shaped | A: PHE356 | Dieckol |
Dieckol - A: MET383 | 5.1850 | Hydrophobic | Pi-Alkyl | A: MET383 | Dieckol |
Dieckol - A: MET383 | 5.3465 | Hydrophobic | Pi-Alkyl | A: MET383 | Dieckol |
Dieckol - A: ALA386 | 4.6125 | Hydrophobic | Pi-Alkyl | A: ALA386 | Dieckol |
Dieckol - A: ALA386 | 4.5717 | Hydrophobic | Pi-Alkyl | A: ALA386 | Dieckol |
Dieckol - A: ALA387 | 5.4374 | Hydrophobic | Pi-Alkyl | A: ALA387 | Dieckol |
Dieckol - A: ALA386 | 4.9676 | Hydrophobic | Pi-Alkyl | A: ALA386 | Dieckol |
Dieckol - E: VAL404 | 4.9313 | Hydrophobic | Pi-Alkyl | E: VAL404 | Dieckol |
Interactions-8,8-Bieckol | Distance Å | Bonding | Bonding Types | Target | Ligand |
A: ARG393: HH21 - 8,8-Bieckol: O24 | 2.9012 | Hydrogen Bond | Conventional Hydrogen Bond | A: ARG393: HH21 | 8,8-Bieckol: O24 |
A: ARG393: HH21 - 8,8-Bieckol: O34 | 2.2271 | Hydrogen Bond | Conventional Hydrogen Bond | A: ARG393: HH21 | 8,8-Bieckol: O34 |
E: ARG395: HE - 8,8-Bieckol: O45 | 2.4215 | Hydrogen Bond | Conventional Hydrogen Bond | E: ARG395: HE | 8,8-Bieckol: O45 |
E: GLY490: HN - 8,8-Bieckol: O3 | 2.2512 | Hydrogen Bond | Conventional Hydrogen Bond | E: GLY490: HN | 8,8-Bieckol: O3 |
8,8-Bieckol: H57 - E: ASP392: OD1 | 2.6917 | Hydrogen Bond | Conventional Hydrogen Bond | E: ASP392: OD1 | 8,8-Bieckol: H57 |
8,8-Bieckol: H66 - E: ASP392: OD2 | 2.6695 | Hydrogen Bond | Conventional Hydrogen Bond | E: ASP392: OD2 | 8,8-Bieckol: H66 |
8,8-Bieckol: H70 - E: ASP392: O | 2.2937 | Hydrogen Bond | Conventional Hydrogen Bond | E: ASP392: O | 8,8-Bieckol: H70 |
8,8-Bieckol: H75 - E: ASP392: OD2 | 2.4938 | Hydrogen Bond | Conventional Hydrogen Bond | E: ASP392: OD2 | 8,8-Bieckol: H75 |
8,8-Bieckol: H76 - E: GLY391: O | 2.6050 | Hydrogen Bond | Conventional Hydrogen Bond | E: GLY391: O | 8,8-Bieckol: H76 |
A: THR324: HB - 8,8-Bieckol: O17 | 2.7874 | Hydrogen Bond | Carbon Hydrogen Bond | A: THR324: HB | 8,8-Bieckol: O17 |
A: GLY354: HA2 - 8,8-Bieckol: O35 | 2.6753 | Hydrogen Bond | Carbon Hydrogen Bond | A: GLY354: HA2 | 8,8-Bieckol: O35 |
E: GLY490: HA1 - 8,8-Bieckol: O3 | 2.9183 | Hydrogen Bond | Carbon Hydrogen Bond | E: GLY490: HA1 | 8,8-Bieckol: O3 |
E: GLY490: HA1 - 8,8-Bieckol: O15 | 2.5716 | Hydrogen Bond | Carbon Hydrogen Bond | E: GLY490: HA1 | 8,8-Bieckol: O15 |
E: ARG395: NH2 - 8,8-Bieckol | 4.0496 | Electrostatic | Pi-Cation | E: ARG395: NH2 | 8,8-Bieckol |
E: ASP392: OD1 - 8,8-Bieckol | 3.7168 | Electrostatic | Pi-Anion | E: ASP392: OD1 | 8,8-Bieckol |
E: ASP392: OD2 - 8,8-Bieckol | 3.3036 | Electrostatic | Pi-Anion | E: ASP392: OD2 | 8,8-Bieckol |
A: ALA387: HA - 8,8-Bieckol | 2.6522 | Hydrophobic | Pi-Sigma | A: ALA387: HA | 8,8-Bieckol |
8,8-Bieckol - E: ILE489 | 4.7007 | Hydrophobic | Pi-Alkyl | E: ILE489 | 8,8-Bieckol |
8,8-Bieckol - A: ALA386 | 4.3628 | Hydrophobic | Pi-Alkyl | A: ALA386 | 8,8-Bieckol |
8,8-Bieckol - A: ALA387 | 4.7288 | Hydrophobic | Pi-Alkyl | A: ALA387 | 8,8-Bieckol |
Interactions-Phlorofucofuroeckol B | Distance Å | Bonding | Bonding Types | Target | Ligand |
Phlorofucofuroeckol B: H58 - A: GLU37: OE1 | 2.0637 | Hydrogen Bond | Conventional Hydrogen Bond | A: GLU37: OE1 | Phlorofucofuroeckol B: H58 |
Phlorofucofuroeckol B: H60 - E: GLN396: OE1 | 2.7084 | Hydrogen Bond | Conventional Hydrogen Bond | E: GLN396: OE1 | Phlorofucofuroeckol B: H60 |
Phlorofucofuroeckol B: H62 - E: TYR491: OH | 2.6045 | Hydrogen Bond | Conventional Hydrogen Bond | E: TYR491: OH | Phlorofucofuroeckol B: H62 |
E: LYS390: NZ - Phlorofucofuroeckol B | 4.9696 | Electrostatic | Pi-Cation | E: LYS390: NZ | Phlorofucofuroeckol B |
E: LYS390: NZ - Phlorofucofuroeckol B | 4.6371 | Electrostatic | Pi-Cation | E: LYS390: NZ | Phlorofucofuroeckol B |
E: LYS390: HZ3 - Phlorofucofuroeckol B | 2.6050 | Hydrogen Bond;Electrostatic | Pi-Cation;Pi-Donor Hydrogen Bond | E: LYS390: HZ3 | Phlorofucofuroeckol B |
E: ASP393: OD1 - Phlorofucofuroeckol B | 4.0933 | Electrostatic | Pi-Anion | E: ASP393: OD1 | Phlorofucofuroeckol B |
E: ASP393: OD1 - Phlorofucofuroeckol B | 4.6346 | Electrostatic | Pi-Anion | E: ASP393: OD1 | Phlorofucofuroeckol B |
E: TYR440 - Phlorofucofuroeckol B | 5.2464 | Hydrophobic | Pi-Pi Stacked | E: TYR440 | Phlorofucofuroeckol B |
E: TYR491 - Phlorofucofuroeckol B | 5.2086 | Hydrophobic | Pi-Pi T-shaped | E: TYR491 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: ALA386 | 5.2691 | Hydrophobic | Pi-Alkyl | A: ALA386 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - E: VAL404 | 4.6856 | Hydrophobic | Pi-Alkyl | E: VAL404 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: ALA386 | 5.1446 | Hydrophobic | Pi-Alkyl | A: ALA386 | Phlorofucofuroeckol B |
SARS CoV-2 Spike/TMPRSS 2 | |||||
Interactions-Remdesivir | Distance Å | Bonding | Bonding Types | Target | Ligand |
Remdesivir: H47 - B: GLY165: O | 2.8345 | Hydrogen Bond | Conventional Hydrogen Bond | B: GLY165: O | Remdesivir: H47 |
Remdesivir: H56 - A: VAL687: O | 2.5341 | Hydrogen Bond | Conventional Hydrogen Bond | A: VAL687: O | Remdesivir: H56 |
Remdesivir: H57 - B: ARG313: O | 2.8787 | Hydrogen Bond | Conventional Hydrogen Bond | B: ARG313: O | Remdesivir: H57 |
A: TRP633: HE1 - Remdesivir: N30 | 2.8480 | Hydrogen Bond | Conventional Hydrogen Bond | A: TRP633: HE1 | Remdesivir: N30 |
B: ARG313: H - Remdesivir: N26 | 2.4144 | Hydrogen Bond | Conventional Hydrogen Bond | B: ARG313: H | Remdesivir: N26 |
B: ARG313: HH11 - Remdesivir: N26 | 3.0912 | Hydrogen Bond | Conventional Hydrogen Bond | B: ARG313: HH11 | Remdesivir: N26 |
Remdesivir: H43 - A: ARG685: O | 2.9438 | Hydrogen Bond | Carbon Hydrogen Bond | A: ARG685: O | Remdesivir: H43 |
A: ARG634: HD3 - Remdesivir: O8 | 2.4125 | Hydrogen Bond | Carbon Hydrogen Bond | A: ARG634: HD3 | Remdesivir: O8 |
B: ALA312: HA - Remdesivir: O24 | 2.9702 | Hydrogen Bond | Carbon Hydrogen Bond | B: ALA312: HA | Remdesivir: O24 |
B: ARG167: NH2 - Remdesivir | 4.0186 | Electrostatic | Pi-Cation | B: ARG167: NH2 | Remdesivir |
B: ARG167: NH2 - Remdesivir | 4.1807 | Electrostatic | Pi-Cation | B: ARG167: NH2 | Remdesivir |
B: ARG313: NH1 - Remdesivir | 4.6223 | Electrostatic | Pi-Cation | B: ARG313: NH1 | Remdesivir |
A: ARG634: H - Remdesivir | 2.6939 | Hydrogen Bond | Pi-Donor Hydrogen Bond | A: ARG634: H | Remdesivir |
B: GLY166: O - Remdesivir | 2.7178 | Other | Pi-Lone Pair | B: GLY166: O | Remdesivir |
Remdesivir: C40 - A: ARG683 | 4.2866 | Hydrophobic | Alkyl | A: ARG683 | Remdesivir: C40 |
Remdesivir: C42 - A: ARG634 | 4.5767 | Hydrophobic | Alkyl | A: ARG634 | Remdesivir: C42 |
Remdesivir- A: ARG634 | 4.3767 | Hydrophobic | Pi-Alkyl | A: ARG634 | Remdesivir |
Remdesivir- B: ARG167 | 4.0580 | Hydrophobic | Pi-Alkyl | B: ARG167 | Remdesivir |
Remdesivir- B: ARG167 | 3.7030 | Hydrophobic | Pi-Alkyl | B: ARG167 | Remdesivir |
Interactions-Chloroquine | Distance Å | Bonding | Bonding Types | Target | Ligand |
A: ALA684: H - Chloroquine: N13 | 2.26467 | Hydrogen Bond | Conventional Hydrogen Bond | A: ALA684: H | Chloroquine: N13 |
Chloroquine: H36 - B: GLY165: O | 2.8385 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Chloroquine: H36 |
Chloroquine: H39 - B: GLY165: O | 3.08589 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Chloroquine: H39 |
Chloroquine: H41 - A: VAL687: O | 2.71398 | Hydrogen Bond | Carbon Hydrogen Bond | A: VAL687: O | Chloroquine: H41 |
Chloroquine: H42 - B: GLY165: O | 2.44242 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Chloroquine: H42 |
A: SER637: HG - : Chloroquine | 2.80972 | Hydrogen Bond | Pi-Donor Hydrogen Bond | A: SER637: HG | Chloroquine |
Chloroquine: C22 - A: ALA688 | 3.78942 | Hydrophobic | Alkyl | A: ALA688 | Chloroquine: C22 |
Chloroquine: C22 - B: ARG313 | 4.43767 | Hydrophobic | Alkyl | B: ARG313 | Chloroquine: C22 |
Chloroquine - A: ARG683 | 4.80707 | Hydrophobic | Pi-Alkyl | A: ARG683 | Chloroquine |
Chloroquine - A: ARG685 | 4.25457 | Hydrophobic | Pi-Alkyl | A: ARG685 | Chloroquine |
Chloroquine - A: ARG685 | 3.99115 | Hydrophobic | Pi-Alkyl | A: ARG685 | Chloroquine |
Interactions-Hydroxychloroquine sulfate | Distance Å | Bonding | Bonding Types | Target | Ligand |
A: ALA684: H - Hydroxychloroquine sulfate: N17 | 2.27755 | Hydrogen Bond | Conventional Hydrogen Bond | A: ALA684: H | Hydroxychloroquine sulfate: N17 |
Hydroxychloroquine sulfate: H28 - B: GLY165: O | 2.37459 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Hydroxychloroquine sulfate: H28 |
Hydroxychloroquine sulfate: H29 - B: GLY165: O | 2.80296 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Hydroxychloroquine sulfate: H29 |
Hydroxychloroquine sulfate: H45 - B: GLY165: O | 2.78093 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Hydroxychloroquine sulfate: H45 |
Hydroxychloroquine sulfate: H46 - B: GLY165: O | 2.57049 | Hydrogen Bond | Carbon Hydrogen Bond | B: GLY165: O | Hydroxychloroquine sulfate: H46 |
Hydroxychloroquine sulfate: H47 - A: VAL687: O | 2.46144 | Hydrogen Bond | Carbon Hydrogen Bond | A: VAL687: O | Hydroxychloroquine sulfate: H47 |
Hydroxychloroquine sulfate: H48 - A: VAL687: O | 2.7889 | Hydrogen Bond | Carbon Hydrogen Bond | A: VAL687: O | Hydroxychloroquine sulfate: H48 |
A: SER637: HG - Hydroxychloroquine sulfate | 2.78346 | Hydrogen Bond | Pi-Donor Hydrogen Bond | A: SER637: HG | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: ARG683 | 4.75047 | Hydrophobic | Pi-Alkyl | A: ARG683 | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: ARG685 | 4.28571 | Hydrophobic | Pi-Alkyl | A: ARG685 | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: ALA684 | 5.24405 | Hydrophobic | Pi-Alkyl | A: ALA684 | Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate - A: ARG685 | 3.95296 | Hydrophobic | Pi-Alkyl | A: ARG685 | Hydroxychloroquine sulfate |
Interactions-6,6-Bieckol | Distance Å | Bonding | Bonding Types | Target | Ligand |
6,6-Bieckol: H65 - B: THR827: OG1 | 2.4295 | Hydrogen Bond | Conventional Hydrogen Bond | B: THR827: OG1 | 6,6-Bieckol: H65 |
6,6-Bieckol: H66 - B: VAL826: O | 1.8942 | Hydrogen Bond | Conventional Hydrogen Bond | B: VAL826: O | 6,6-Bieckol: H66 |
B: ASN824: HA - 6,6-Bieckol: O36 | 2.8434 | Hydrogen Bond | Carbon Hydrogen Bond | B: ASN824: HA | 6,6-Bieckol: O36 |
B: ASN824: HD22 - 6,6-Bieckol | 2.6394 | Hydrogen Bond | Pi-Donor Hydrogen Bond | B: ASN824: HD22 | 6,6-Bieckol |
A: PRO288: HG3 - 6,6-Bieckol | 2.4698 | Hydrophobic | Pi-Sigma | A: PRO288: HG3 | 6,6-Bieckol |
A: PHE194 - 6,6-Bieckol | 5.1410 | Hydrophobic | Pi-Pi T-shaped | A: PHE194 | 6,6-Bieckol |
6,6-Bieckol - A: PRO288 | 4.9211 | Hydrophobic | Pi-Alkyl | A: PRO288 | 6,6-Bieckol |
6,6-Bieckol - A: PRO354 | 5.4241 | Hydrophobic | Pi-Alkyl | A: PRO354 | 6,6-Bieckol |
Interactions-Dieckol | Distance Å | Bonding | Bonding Types | Target | Ligand |
Dieckol: H75 - B: ASP820: OD2 | 2.3269 | Hydrogen Bond | Conventional Hydrogen Bond | B: ASP820: OD2 | Dieckol: H75 |
A: PHE194: HA - Dieckol: O54 | 2.8352 | Hydrogen Bond | Carbon Hydrogen Bond | A: PHE194: HA | Dieckol: O54 |
A: PRO288: HD2 - Dieckol: O34 | 2.7823 | Hydrogen Bond | Carbon Hydrogen Bond | A: PRO288: HD2 | Dieckol: O34 |
A: PRO288: HG3 - Dieckol | 2.8002 | Hydrophobic | Pi-Sigma | A: PRO288: HG3 | Dieckol |
A: PHE357 - Dieckol | 5.3177 | Hydrophobic | Pi-Pi T-shaped | A: PHE357 | Dieckol |
Dieckol - A: PRO288 | 4.7037 | Hydrophobic | Pi-Alkyl | A: PRO288 | Dieckol |
Dieckol - A: PRO288 | 5.1331 | Hydrophobic | Pi-Alkyl | A: PRO288 | Dieckol |
Dieckol - A: PRO354 | 4.5933 | Hydrophobic | Pi-Alkyl | A: PRO354 | Dieckol |
Interactions-Phlorofucofuroeckol B | Distance Å | Bonding | Bonding Types | Target | Ligand |
A: PHE357: H - Phlorofucofuroeckol B: O38 | 2.3777 | Hydrogen Bond | Conventional Hydrogen Bond | A: PHE357: H | Phlorofucofuroeckol B: O38 |
Phlorofucofuroeckol B: H56 - A: THR287: OG1 | 2.8288 | Hydrogen Bond | Conventional Hydrogen Bond | A: THR287: OG1 | Phlorofucofuroeckol B: H56 |
Phlorofucofuroeckol B: H57 - A: GLU289: OE2 | 2.0276 | Hydrogen Bond | Conventional Hydrogen Bond | A: GLU289: OE2 | Phlorofucofuroeckol B: H57 |
Phlorofucofuroeckol B: H59 - A: CYS241: O | 2.0033 | Hydrogen Bond | Conventional Hydrogen Bond | A: CYS241: O | Phlorofucofuroeckol B: H59 |
A: PRO288: HD2 - Phlorofucofuroeckol B: O33 | 2.4845 | Hydrogen Bond | Carbon Hydrogen Bond | A: PRO288: HD2 | Phlorofucofuroeckol B: O33 |
A: ARG240: NH1 - Phlorofucofuroeckol B | 3.1654 | Electrostatic | Pi-Cation | A: ARG240: NH1 | Phlorofucofuroeckol B |
A: ARG240: NH1 - Phlorofucofuroeckol B | 4.0653 | Electrostatic | Pi-Cation | A: ARG240: NH1 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: PHE357 | 5.5184 | Hydrophobic | Pi-Pi T-shaped | A: PHE357 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: ALA243 | 5.3830 | Hydrophobic | Pi-Alkyl | A: ALA243 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: PRO288 | 4.7384 | Hydrophobic | Pi-Alkyl | A: PRO288 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: PRO354 | 4.5468 | Hydrophobic | Pi-Alkyl | A: PRO354 | Phlorofucofuroeckol B |
Phlorofucofuroeckol B - A: ALA243 | 4.5363 | Hydrophobic | Pi-Alkyl | A: ALA243 | Phlorofucofuroeckol B |
Table 4: Interactions types and distances of three positive controls (Remdesivir, chloroquine and hydroxychloroquine sulfate) and the three better compounds [Diekcol (6), 8,8-Bieckol (9) and Phlorofucofuroeckol B (10)] with SARS CoV-2-RBD/ACE2 and [6,6-Bieckol (7), Diekcol (6) and Phlorofucofuroeckol B (10)] with SARS CoV-2-Spike/TMPRSS2, respectively.
In silico ADMET analysis
ADMET properties were assessed by ADMET subprotocol of Discovery Studio 2019 software. It compiles pharmacokinetic properties for selected ligands along with control compounds (remdesivir, chloroquine and hydroxychloroquine sulfate) in Table 2. Basically, the poor solubility associates with poor absorption. So the water solubility (log S) of a compound significantly influences its absorption features. The predicted log S values of all top four compounds [dieckol (6), 6,6-Bieckol (7), 8,8-Bieckol (9) and phlorofucofuroeckol B (10)] were within the tolerable limit. Donor and acceptor of hydrogen bonding are essentials of Lipinski rule and all the ligands were displayed within the acceptable range of drug-likeliness. CaCO2 intestinal cell line permeability is measured in nm/sec and is meaningful for intestinal absorption. Its value was lower than the limited value for among the top four tested ligands. The log hERG (log IC50) values for dieckol (6), phlorofucofuroeckol B (10), 8,8-Bieckol (9) and 6,6-Bieckol (7) display the finest results among eleven ligands. The negative value of log hERG shows that the lower the value of log hERG, the lesser is the blockage of K+ ion channels [37]. The results of in silico ADMET studies implied that dieckol (6) and phlorofucofuroeckol B (10) exhibited fine pharmacokinetic profile. Further, the predicted toxicity data (AMES toxicity, hepatotoxicity, skin sensitization values) reveal that the lead compounds have no toxicity and present demanded range. Henceforth they could be foreseen as safe for drug development against human epidemics of SARS-CoV-2.
The mechanisms of antiviral actions of algal bioactive compounds include direct virucidal action, inhibition of viral attachment to host cells, inhibition of virus internalization and uncoating in the target cell, inhibition of viral transcription and replication and improvement of antiviral immune responses in host cells [39].
Several reports have done that the routes of SARS CoV-2 protein targets, structures and models (Main Protease, Papainlike protease, Spike RBD, Spike monomer and trimer etc) administration can affect the nature of the treatment toward SARS CoV-2. In the meantime, it is present different ligands having antibody, peptide and small molecules are used to prevent or stop the activities of the disease. The all documents such as targets, structure, models, therapeutics... etc. are present in website, data hub or server systems [40-43].
For example, using the homology modeling models of the Spike glycoprotein and SARS CoV-2 protease 3CLPRO have developed and docking analysis were performed by Hall and Ji 2020, utilizing previously known approved compounds. They suggested several potent inhibitors on the 3CLPRO main proteinase activity including; Zanamivir approved for the treatment of influenza A and B viruses, Indinavir and Saquinavir for treatment of HIV, Remdesivir at experimental stages that has shown clinical activity against the SARS-coronavirus, Ebola virus, and possibly the SARS CoV-2, Flavin Adenine Dinucleotide (FAD) and Coenzyme A [44]. It is also reported that, the aflavin was able to dock in the catalytic pocket near the active site of RdRp in SARS CoV‐2, SARS CoV, and MERS CoV in the two different molecular docking methods [45].
Besides these, the study [46] estimates antagonists of SARS CoV-2 Mpro, SARS CoV-3CLpro, ACE2 Receptor and NSP12 RNA Polymerase against COVID-19, based on already approved 28 drugs, using last disease mechanisms discoveries. Further, it exhibited that hydroxychloroquine, chloroquine were not showed effective, as monotherapies, against COVID-19 or lung cell receptors. Herein, this fact was once again revealed at the molecular level, using silico methods, and the results were validated that chloroquine is not a suitable and effective drug for the treatment of COVID-19 in this article.
Based on these results, molecular docking for our study was performed to explain the effect of the top three molecules amongst the selected 11 compounds against both targets;SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/TMPRSS2. These targets play important roles in prevent and transmission pathways of the related virus and considered as therapeutic targets for disease treatment. Dieckol (6) efficiently docked to the hydrophobic groove of SARS CoV-2-RBD/ACE2. Following, 8,8-Bieckol (9) and Phlorofucofuroeckol B (10) interact with the same target. Dieckol (6) compound has similar behavior as 8,8-Bieckol (9). Furthermore, these compounds display good activity with SARS CoV-2-RBD/ACE2 due to hydroxyl groups in their frame structures. Dieckol and diphlorethohydroxycarmalol phlorotanins isolated from Ecklonia cava Kjelman strongly inhibited HIV-1 Reverse Transcriptase (RT) activity and moderately inhibited HIV- 1 protease activity. Dieckol inhibited the syncytium formation and penetration of HIV into cells, viral replication, and virus induced lytic effects [47].
For another target, (SARS CoV-2-Spike/TMPRSS2) 6,6-Bieckol (7) bounds in the position of two proteins interface with the lowest binding energy (-9.177 kcal//mol) in other compounds. In the meantime, among the polyphenolic compounds 6,6-Bieckol isolated from Ecklonia cava was found to be inhibitory effect on HIV-1 induced syncytia formation, cell–virus and cell–cell fusion, viral entry, HIV-1 RT enzyme activity and cytopathic effects of HIV-1 in a dose-dependent manner [48]. Second one is Diekcol (6). Dieckol, eckol, 7-phloroeckol, fucodiphloroethol G and phlorofucofuroeckol phlorotannins exhibited inhibitory effect on SARS CoV 3CLpro activity in a dose-dependent fashion. Among these compounds Dieckol was found to be the most efficient molecule on inhibiting cleavage activity of the 3CLpro enzyme. Docking experiments also supported the important inhibitory effect of Dieckol on SARS CoV 3CLpro enzyme [49]. The last, it shows third good binding affinity value of Phlorofucofuroeckol B (10) toward the target. Interestingly, Kwon HJ et al. reported that, Phlorofucofuroeckol have inhibited Porcine Epidemic Diarrhea Virus PEDV which is belonging to Coronaviridae family of viruses through inhibiting its attachment to the target cell. They also showed that Dieckol, 7-Phloroeckol and Eckol was also had inhibitory effect on virus and target cell attachment. Dieckol, Eckol and Phlorofucofuroeckol displayed strong inhibition of hemaglutination which have been completely blocking virus attachment at intestinal enterocytes. This antiviral activity attributed to a strong interaction with S protein on the outer surface of PEDV which results in restricts the viral adsorption. Dieckol and Phlorofucofuroeckol were found to be have stronger inhibitory effects on the late stage viral replication [50]. However, to our knowledge there is no publication on in silico analysis for algal phenolic compounds’ binding affinity at ACE2 and TMPRSS2 receptors SARS-COV-2 binding surfaces.
In this study showed that an in silico model of algal molecules interactivity on SARS CoV-2-RBD/ACE2 and SARS CoV-2-Spike/ TMPRSS2 receptor. In general, computational observations suggests that the hydroxyl group of the related compounds, which are largely responsible for antiviral activities, is a good evidence to refute the existence of current belief. However, to date, no studies have shown an association of the inhibitory effect of these molecules with inflammation of SARS-CoV-2. In summary, this research, based on a broad theoretical approach, can be a guide for future research to learn about molecules selected from algae in the treatment or prevention of SARS CoV-2. Pre-clinic studies could be promise as candidate clinical potential in these molecules over SARS – CoV-2 inflammation or different pandemics in future.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The datasets generated for this study are available on request to the corresponding authors.